The independent source for health policy research, polling, and news.
2,661-2,680 of 4,005 results
A federal judge in Texas last month issued a preliminary injunction barring the government from enforcing a rule allowing insurers to refuse to insure dialysis patients who get premium assistance from charity groups.
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
The FDA has approved dozens of new cancer medications in recent years, but few offer the benefits that patients seek.
Insurers and care providers say efforts to fix how consumers are notified also raise concerns.
With federal investigators bearing down on his committee, Rep. Tom Price, R-Ga., who is line to be secretary of the Department of Health and Human Services, showed little restraint in investing in health companies.
Luke Whitbeck’s life was saved by a rare disease drug, but it costs $300,000 a year.
With announcements of placements in residencies expected in March, medical education groups and hospitals say they’re unsure how to proceed.
Despite questions about Lupron’s lasting side effects and minimal study into its safety, the FDA sped approval of the drug to market. Years later, some young women are still living with the consequences.
Concerns over U.S. Rep. Tom Price’s answers about stock trades led Senate Democrats to boycott a committee vote that would have moved his nomination to the Senate floor.
A new study, though small, finds extensive damage to commonly used medical scopes that could trap dangerous bacteria. That raises concerns about the potential for more outbreaks.
The device, known as Evzio, administers just enough naloxone to stabilize someone who has overdosed on drugs. But its manufacturer, Kaleo, may be positioning itself to find profits in a dire health care crisis.
The HMO blew two deadlines to supply information required by the state to monitor Medi-Cal managed care plans. Kaiser says it is “taking steps” to resolve the problem.
Rep. Tom Price, up for running HHS under President Trump, helped a company that became a top campaign donor, records show.
The Consumer Financial Protection Bureau reports in a new study that 59 percent of people contacted by a debt collector had outstanding medical bills.
Letters sent to Medicare from U.S. Rep. Tom Price, President Trump's pick to run HHS, supported physicians as well as drug or device makers, records show.
Intense, “high touch” care that focuses on housing as well as health care brings down medical costs for the most expensive patients. But it’s been hard to replicate successful programs.
Donald Trump’s pick to run HHS has been under fire for trading health care stocks but at least six senators at his confirmation hearings also own such stocks.
Federal officials release names of insurers who ranked poorly in a recent review of their online directories’ accuracy.
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
© 2026 KFF